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Abstract
Mitochondrial respiratory chain dysfunction has been identified in a number of neurodegen-
erative disorders. Infantile cerebellar-retinal degeneration associated with mutations in the
mitochondrial aconitase 2 gene (ACO2) has been recently described as a neurodegenera-
tive disease of autosomal recessive inheritance. To date there is no biomarker for ACO2
deficiency and diagnosis relies on genetic analysis. Here we report global metabolic profiling
in eight patients with ACO2 deficiency. Using an LC-MS-based metabolomics platform we
have identified several metabolites with affected plasma concentrations including the tricar-
boxylic acid cycle metabolites cis-aconitate, isocitrate and alpha-ketoglutarate, as well as
phosphoenolpyruvate and hydroxybutyrate. Taken together we report a diagnostic meta-
bolic fingerprint for mitochondrial aconitase 2 deficiency.
Introduction
The Krebs cycle (i.e. citric acid cycle; TCA cycle) is a nexus of carbohydrate, fat and protein
metabolism. Eight enzymatic reactions comprise the core TCA catalytic cycle (S1 Fig), which
ultimately oxidizes acetate (acetyl-CoA) into carbon dioxide and water. The cycle converts nic-
otinamide adenine dinucleotide (NAD+) into reduced NAD+ (NADH), flavin adenine dinu-
cleotide (FAD) into FADH2, and guanosine diphosphate (GDP) and inorganic phosphate (Pi)
into guanosine triphosphate (GTP). The NADH and FADH2 generated in the TCA cycle are
subsequently used by the oxidative phosphorylation pathway to generate energy-rich adeno-
sine triphosphate (ATP), which constitutes the main source of cellular energy thereby sustain-
ing mitochondrial respiratory chain activity [1]. In eukaryotes, the citric acid cycle occurs in
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the mitochondrial matrix, and is of critical importance to all organisms utilizing oxygen for
cellular respiration.
ACO2 is an iron-sulphur (4Fe-4S) cluster protein that catalyzes the reversible isomerization
of citrate to isocitrate within the mitochondrial citric acid cycle. In addition to supplying the
mitochondrial respiratory chain through the generation of the reducing molecules NADH and
FADH2, the citric acid cycle also generates precursors for the biosynthesis of several endoge-
nous compounds, e.g. in fatty acid synthesis and gluconeogenesis.
Infantile cerebellar-retinal degeneration associated with mutations in the mitochondrial
aconitase 2 gene (ACO2) has been recently described in eight individuals from two unrelated
Arab families [2] and three patients of French or Algerian descent [3]. Patients share a similar
clinical phenotype with ophthalmological abnormalities including optic atrophy, retinal
degeneration and strabismus, axial hypotonia, ataxia, progressive microcephaly and various
types of seizures often triggered by infection. The disease follows a neurodegenerative course
but survival into adulthood is possible. Cerebral imaging reveals progressive brain atrophy
affecting primarily the cerebellum as well as thinning of the corpus callosum, demyelination
and cortical atrophy of the frontal and temporal lobes. Interestingly two patients with ACO2
mutations, reported by Metodiev et al., had a different phenotype with isolated optic atrophy
with onset in early childhood [3].
With respect to biomarkers, severe metabolic acidosis and hyperglycemia was described in
one of the two patients reported by Metodiev et al [3], while all patients reported by Spiegel
et al. had normal serum and CSF lactate, pyruvate, alanine and organic acids in urine as well as
a normal levels of mitochondrial respiratory chain enzymes and pyruvate dehydrogenase
activity; there was only slight reduction in the oxidation of glutamate [2]. Thus ACO2 defi-
ciency lacks typical mitochondrial disease biomarkers, similar to other citric acid cycle defects
such as succinate dehydrogenase deficiency [4], succinyl-CoA synthase deficiency [5] and
fumarate hydratase deficiency [6, 7].
The diagnosis of ACO2 deficiency relies on genetic testing or enzyme activity assay [8]. A
total of seven missense mutations (p.Gly259Asp, p.Ser112Arg, p.Leu74Val, p.Gly661Arg, p.
Lys736Asn, p.Pro712Lys, and p.Arg607Cit) and one frameshift mutation (p.Lys776Asnfs49)
have been reported [2, 3, 8]. All nucleotide changes involve highly conserved positions, which
are predicted to be deleterious. However, the p.Leu74Val variant has been reported in the SNP
database (rs141772938; MAF 0.003) [3].
Given the unspecific encephalomyopathic presentation of ACO2 deficiency and lack of a
specific disease biomarker, we were interested in identifying novel disease-associated metabo-
lites or metabolite profiles by clinical metabolomics. Mass-spectrometry based metabolomics
has led to the discovery of novel biomarkers and disease-associated metabolic profiles in as yet
uncharacterized genetic diseases [9, 10]. Here we performed comparative untargeted metabo-
lomics on the plasma of eight ACO2 deficient patients of four unrelated families against a
matched control cohort and report a diagnostic metabolic fingerprint in plasma for mitochon-
drial aconitase 2 deficiency.
Materials and methods
Ethics statement
Parents or the legal guardians of all patients have given full written informed consent for partici-
pation in a study on metabolic-genetic research into early onset epileptic encephalopathies (EE)
and a metabolome study, respectively. Parents or the legal guardians of the control cohort have
given full written informed consent for participation in the metabolome study. Both studies
have been approved by the Institutional Review Board of the Kanton of Zurich. All procedures
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followed were in accordance with the ethical standards of the responsible local Ethics committee
(institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000.
Informed consent
Parents or the legal guardians of all patients have given full written informed consent for par-
ticipation in the study.
Patients
Eight patients from four different families (F1-P1/P2, F2-P1/P2/P3, F3-P1/P2, F4-P1) were
included in this study with an age range from 22 months to 21 years (Table 1). Three families
(F1-P1/P2, F2-P1/P2/P3, F3-P1/P2) were of Arab origin, one family of Caucasian origin
(F4-P1). F1-P1/P2 and F2-P1/P2/P3 have been previously published [2]. Disease onset was
between 2 and 6 months. The clinical phenotype was mainly characterized by severe muscular
hypotonia, seizures, strabismus, optic atrophy, ataxia, profound developmental delay and sec-
ondary microcephaly. Table 1 provides a summary of the clinical, biochemical, imaging and
Table 1. Overview of clinical, genetic and imaging findings from eight patients (comprising four families, F1-F4) with ACO2 deficiency.
F1-P1 F1-P2 F2-P1 F2-P2 F2-P3 F3-P1 F3-P2 F4-P1
Patients
Gender Female Male Female Female Female Female Female Female
Ethnicity Arab Arab Arab Arab Arab Arab Arab Caucasian
Current age 10y 4y 12y 11y 6y 17y 14y † at 46mo
Genotype c.336C>G/
c.336C>G
c.336C>G/
c.336C>G
c.336C>G/
c.336C>G
c.336C>G/
c.336C>G
c.336C>G/
c.336C>G
c.336C>G/
c.336C>G
c.336C>G/
c.336C>G
c.1859G>A/
c.2048G>T
p.Ser112Arg/
p.Ser112Arg
p.Ser112Arg/
p.Ser112Arg
p.Ser112Arg/
p.Ser112Arg
p.Ser112Arg/
p.Ser112Arg
p.Ser112Arg/
p.Ser112Arg
p.Ser112Arg/
p.Ser112Arg
p.Ser112Arg/
p.Ser112Arg
p.Gly620Asp/
p.Gly683Val
Phenotype
Hyptonia + + + + + + + +
Ataxia + + + + + + + +
Optic atrophy + + + + + + + +
Strabismus + + + + + + + +
Seizures + - + + + - + +
Microcephaly + + + + + + + +
Intellectual
disability
+ + + + + + + +
Sensorineuronal
Hearing loss
+ + na na - + na -
Failure to thrive + + + + + + + +
Imaging findings
(Age at MRI) 4y 12y 7mo 16mo 1y 3y na 34mo
Cerebral atrophy + + + + + + na +
Cerebellar atrophy + + - - + + na +
Thin CC + - + - - + na +
White matter
abnormalities
+ + - + - + na +
na = not available; F1 and F2 have been previously published [2].
https://doi.org/10.1371/journal.pone.0176363.t001
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genetic findings. The control cohort comprised 30 plasma samples (age range 1.8–17.0; mean
12.15 ±3.58, median 12.25 years) admitted to the Children’s Hospital for unrelated reasons.
Reagents
All reference compounds, ultra LC-MS grade solvents and reagents for the metabolomics anal-
ysis were purchased from Sigma-Aldrich AG (Buchs, Switzerland).
Genetic studies
Five patients (F1-P1/P2; F2-P1/P2/P3) were previously found to harbor the homozygous path-
ogenic mutation c.336C>G in the ACO2 gene [2]. Two other siblings residing in the same vil-
lage also tested positive for this mutation (Fig 1). In brief, genomic DNA was extracted from
whole blood using the FlexiGene DNA kit (Qiagen, Hilden, Germany) according to the manu-
facturer’s instructions. A PCR based assay was used to amplify the regions in which the muta-
tions are located (primer sequences available upon request). Direct sequence analysis of PCR
products was performed in both forward and reverse directions using the ABI prism 3130
Genetic Analyzer (Applied-Biosystems, Foster City, CA, USA).
In patient F4-P1 whole exome sequencing was performed using the Agilent SureSelectXT
Clinical Research Exome Kit (V5) (Agilent Technologies) with paired-end sequencing (HiSeq
SBS Kit v4, 125 Fwd-125 Rev) on a HiSeq2500 System (Illumina Inc.) on genomic DNA
derived from peripheral blood. Raw fastQ files were aligned to the hg19 reference genome
using NextGene (Softgenetics). Variants observed in at least 16% of reads with sufficient qual-
ity level were analyzed for de novo, compound heterozygous and homozygous calls (with
Minor Allele Frequency 2%). The resulting variants were investigated in silico for deleteri-
ous effects by SIFT, PhyloPhen, LRT, Mutation Taster, Mutation assessor, FATHMM, GERP
and CADD, by associations of the affected gene with epilepsy or intellectual disability and by
literature search for evident functional information. The candidate ACO2 variants were con-
firmed and tested for segregation by Sanger sequencing.
Metabolomics data acquisition and preprocessing
All plasma samples were analyzed by liquid chromatography-mass spectrometry (LC-MS;
Dionex Ultimate XRS3000 UHPLC coupled to a Q-Exactive high resolution, accurate mass
Fig 1. Partial electropherograms from Sanger sequencing showing the mutations in F3-P1 and F4-P1.
On the left side, the homozygous mutation in F3-P1, the heterozygous state of the father of F3-P1 and the
wildtype in a control individual. On the right side the compound heterozygous mutations of patient F4-P1 with
respective heterozygous and wild-type states in the parents.
https://doi.org/10.1371/journal.pone.0176363.g001
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spectrometer (Thermo Scientific, Sunnyvale, CA, USA)). Chromatographic separations were
achieved using a 2.1 x 100mm Kinetex HILIC column (Phenomenex, Torrance, CA, USA).
Mobile phases used were: A) 50% acetonitrile in 5mM ammonium formate (pH 3.2), and B)
90% acetonitrile in 5mM ammonium formate (pH 3.2). Total run time was 15 minutes with a
10 minute linear gradient running from 100% B to 100% A. Solvents were pumped at 400 μL/
minute with a column temperature of 30˚C and sample chamber held at 5˚C. Mass spectro-
metric measurements were acquired in positive and negative ionization modes through the
heated electro-spray ionization (HESI) source. The untargeted metabolomics data set was
acquired with the MS detector in full-scan mode (Full-MS) with data-dependent (dd-MS2)
acquisition of fragment ions from the top-5 most abundant ions per scan. Mass spectrometer
settings for full-MS were as follows: In-source CID 0.0 eV, μscans = 1, resolution = 70,000,
AGC target 1e6, max IT = 35 ms, scan range 67 to 1000 m/z. Detector setting for dd-MS2
were: μscans = 1, resolution = 17,500, AGC target 1e5, max IT = 80 ms, loop count = 5, isola-
tion window 4.0 m/z, NCE 30.0, intensity threshold 1.3e4, apex trigger 2 to 4s.
Raw data were collected in Xcalibur (Thermo) and converted to.mzXML format using the
MSconvert.exe [11]. Data preprocessing was performed in R (x64, v3.1.0) the free software
environment for statistical computing and graphics (http://www.r-project.org/). Feature detec-
tion, retention time correction and peak grouping were done using XCMS [12, 13]. All peaks
of interest were manually inspected (EIC) for peak shape and alignment, and then mined
against the MetaCyc (http://metacyc.org/; [14], Metlin (https://metlin.scripps.edu/;[15]
Human Metabolome (http://www.hmdb.ca/), and KEGG (http://www.kegg.jp/kegg/) data-
bases. Date of the last database access was March 16, 2016. All metabolic pathway annotations
were done in python with mummichog v.1.0.5 [16].
Statistical analysis
Data pretreatment included 1) noise filtering and missing value imputation, where features
missing from at least 75% of data were eliminated 2) sum normalization was performed on
total intensity data, i.e. the sum of all variables for each sample is calculated and used as nor-
malizing factor for each variable. Each variable is then transformed as a fraction of the total
spectral sum. All data scaling, normalization and univariate analysis were performed in R [17].
Multivariate data analysis was performed in SIMCA v13.0.3 (Unimetrics, Malmo¨, Sweden).
Data matrices containing mass over charge (m/z), and normalized ion signal intensity were
analyzed with the unsupervised principle components analysis (PCA; Fig 2A). Orthogonal
projection to a latent structure-discriminant analysis (OPLS-DA; Fig 2B) was used to evaluate
and rank the differential metabolite expression profiles. Relative metabolite ratios were calcu-
lated by comparing the integrated area under curve for the target metabolite. False-discovery
rates were calculated in GraphPad Prism 6 (GraphPad Software Inc.).
Results
Genetic analysis
Whole exome sequencing in patient F4-P1 covered about 96.6% of the targeted region with
20 independent sequence reads and revealed a total of 3 de novo variants, 9 pairs of com-
pound heterozygous and 2 homozygous variants ( 2% Minor Allele Frequency). Taking into
account predicted deleterious effects and associations of the affected gene with epilepsy or
intellectual disability in these candidate variants revealed two novel compound heterozygous
mutations in the gene ACO2 (NM_001098) [2] (Fig 1). The mutations were located in exon 15
(c.1859G>A, p.Gly620Asp) and 16 (c.2048G>T, p.Gly683Val) and were predicted to be dele-
terious by 5 of 6 and 2 of 6 prediction tools, respectively (SIFT (Damaging / Tolerated),
Metabolomics reveals diagnostic metabolic fingerprint for mitochondrial aconitase (ACO2) deficiency
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PolyPhen (Damaging / Benign), LRT (Damaging / Damaging), Mutation Taster (Disease caus-
ing / Disease causing), Mutation assessor (Medium / Neutral), FATHMM (Tolerated / Toler-
ated), CADD score (17 / 14.4).
Metabolomics analysis
The final negative ion data matrix comprised 758 features with p< 0.05 and a fold-change >
1.5 (up or down) between case and cohort sample sets. PCA of the resultant data matrix
revealed differential clustering of the ACO2 cohort against the control cohort with 66% of
the variation within the training set explained by the model and 43% of the variation in the
Fig 2. Multivariate analysis score plots of ACO2-deficient (blue) and matched control plasma (green)
metabolomics data features. A) Principle components analysis (PCA) indicates a clear distinction between
ACO2-deficient and control profiles. F1-F4 correspond to Table 1. Metabolic variations caused by perturbed
metabolic flux due to ACO2-deficiency as well as varying exogenous inputs (e.g. diet, medication) result in
observed data clustering; B) Supervised orthogonal-partial least squares discriminant analysis (OPLS-DA)
with data classification reveals strong feature discrimination between ACO2-deficient and control data sets.
https://doi.org/10.1371/journal.pone.0176363.g002
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training set predicted by the model according to cross validation in the 16th component (R2X
(cum) = 0.66; Q2 (cum) = 0.43) (Fig 2A). Application of supervised OPLS-DA allowed a
detailed differential expression analysis between the ACO2 and control cohorts (R2X (cum) =
0.41; R2Y (cum) = 0.94; Q2 (cum) = 0.88) (Fig 2B). An overall false-discovery rate (FDR) of
0.01 was calculated by an empirical Bayesian method based on moderated t-statistics [18].
Data mining and feature annotation led us to correlate multiple ions to individual metabolites
based on adduct and fragmentation pattern matching. As each of these data features has an
individual signal strength (i.e. ion intensity) an average was calculated for all features attrib-
uted to each metabolite (Table 2).
Table 2. Annotation and average fold-change of data features corresponding to metabolite identifications.
Metabolite KEGG id amatch form m/z bdelta m/z cavg. fold change
cis-Aconitate C00417 M-H[–] 173.0077 -0.0014 -36.9
M(C13)-H[–] 174.0111 -0.0014
M+Cl[–] 208.9847 -0.0006
M+Cl37[–] 210.9818 -0.0005
Isocitrate C00311 M-H[–] 191.0184 -0.0013 -17.7
M+Cl[–] 226.9954 -0.0005
M+Cl37[–] 228.9925 -0.0004
M+ACN-H[–] 232.0462 -0.0001
a-Ketoglutarate C00026 M-H[–] 145.0128 -0.0014 -4.3
M+CH3COO[–] 205.0342 -0.0006
M-CO2+H[1+] 103.0385 -0.0005
Succinate C00042 M+Br[–] 196.9458 0.0009 1.1
M+ Br81[–] 198.9439 0.001
Fumarate C00122 M+Cl37[–] 152.9766 -0.0003 -1.4
Malate C00149 M+ACN-H[–] 174.0394 -0.0014 -1.1
M+CH3COO[–] 193.0342 -0.0006
Phosphoenolpyruvate C00074 M+CH3COO[–] 226.9954 -0.0003 -6.9
M-HCOOK+H[1+] 85.0282 -0.0002
M-CO2+H[1+] 124.9988 -0.0011
Glutamate C00302 M-H[–] 148.0423 -0.0008 1.8
M+HCOO[–] 192.0496 -0.0012
M-C3H4O2+H[1+] 76.0393 -0.0001
M-HCOOH+H[1+] 102.0544 -0.0007
M-CO2+H[1+] 104.0701 -0.0006
M-CO+H[1+] 120.0647 -0.0008
M-H2O+H[1+] 130.0489 -0.001
M+H[1+] 148.0591 -0.0014
M+H2O+H[1+] 166.0711 0
α-,β-hydroxybutyrate C05984 M-H[–] 105.0371 -0.0001 -21.8
M+Na-2H[–] 124.0136 -0.0011
M+HCOO[–] 149.044 -0.0009
M+CH3COO[–] 163.0598 -0.0008
a) adduct or fragment ion matched to metabolite identification
b) mass difference between the calculated and observed mass of the matched feature.
c) average fold change calculated for all matched forms for each annotated metabolite.
https://doi.org/10.1371/journal.pone.0176363.t002
Metabolomics reveals diagnostic metabolic fingerprint for mitochondrial aconitase (ACO2) deficiency
PLOS ONE | https://doi.org/10.1371/journal.pone.0176363 May 2, 2017 7 / 15
Metabolic fingerprint for aconitase deficiency
TCA metabolites
Orthogonal discriminant analysis of the ACO2 vs control negative ionization data matrices
provided a ranked list of differentially expressed features between the sample sets. A meta-
analysis [19] of comparative data matrices from each family against the control cohort revealed
several statistically significant features associated with the citric acid cycle. The series of citric
acid cycle metabolites were tentatively identified from the data as being differentially expressed
in the ACO2 cohort plasma versus the matched control plasma samples (Fig 3). The features
identified in the data as most relevant to a genetic mutation in mitochondrial aconitase were
cis-aconitate and isocitrate. However differential levels of other downstream TCA metabolites
were also observed, including α-ketoglutarate (AKG). Subsequent targeted analysis of individ-
ual ACO2 patient plasma profiles against corresponding age- and sex-matched controls
revealed a 17.7-fold relative decrease for isocitrate, a 36.9-fold average relative reduction of cis-
aconitate, while α-ketoglutarate was reduced 4.3-fold in the ACO2 deficient cohort (Fig 3;
Table 2). The citric acid cycle metabolites ‘downstream’ from α-ketoglutarate i.e. succinate,
malate and fumarate were not dramatically altered.
It should be noted that isocitrate is isobaric with its precursor metabolite, citrate, both hav-
ing the molecular formula C6H8O7. Due to the co-elution and shared monoisotopic mass of
Fig 3. Box-plots indicating differential plasma concentrations of core citric acid cycle metabolites observed between the ACO2 and control
cohorts. All observed ion features corresponding to each annotated metabolite are shown for clarity e.g. adducts, isotopes. Asterisk indicate level of
statistical significance (**** = p < 0.0001; * = p < 0.01; ns = not significant).
https://doi.org/10.1371/journal.pone.0176363.g003
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isocitrate and citrate, we turned to their respective MS/MS fragmentation patterns for confir-
mation. We were able to confirm the presence of lower isocitrate in the study cohort plasma
through the analysis of MS/MS fragmentation of reference isocitrate and citrate aligned with
the observed daughter ions of isocitrate and citrate (obs. [M-H] m/z 173.00755; Metlin m/z
173.0078; Δppm -1.4) (S2 Fig).
Additional metabolites with differential expression in aconitase
deficiency
Multivariate analysis of the ACO2 plasma and control sample cohorts has revealed the differ-
ential expression of various other metabolites which may correspond to the clinical phenotype.
For example, plasma levels of glutamate displayed a 1.8-fold relative increase in ACO2 plasma
when compared to matched controls. The glycolysis metabolites C6 sugar phosphates and
phosphoenolpyruvate were downregulated 22.7-fold and 6.9-fold, respectively. α, β-hydroxy-
butyrate, an end-product of fatty acid beta-oxidation, was downregulated with a 21.8-fold
decrease, (Fig 4).
Fig 4. Box-plots indicating differential plasma concentrations of proposed phenotypically relevant metabolites observed
between the ACO2 and control cohorts. Asterisks indicate level of statistical significance (**** = p < 0.0001).
https://doi.org/10.1371/journal.pone.0176363.g004
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Discussion
The enzyme aconitase (aconitate hydratase; EC 4.2.1.3) exists as cytosolic (ACO1) and mito-
chondrial (ACO2) isoforms, both of which catalyze the reversible isomerization of citrate to
isocitrate (S1 Fig). The primary function of ACO1 is the regulation and maintenance of iron
homeostasis within the cell [20], while ACO2 plays an important role in the regulation of ATP
generation [21]. Both isoforms of aconitase contain a covalently bound [4Fe-4S] iron-sulfur
cluster, which is highly sensitive to oxidation and required for catalytic activity.
In metabolomics analysis of the Acon-knockdown fly study, authors found increased levels
of cis-aconitate, citrate/isocitrate ratio and acetyl-CoA, metabolites proximal to the metabolic
block, while downstream TCA cycle metabolites including alpha-ketoglutarate (AKG), succi-
nate, fumarate and malate were decreased, albeit a mild perturbation [22]. The authors further
identified significantly decreased intermediate metabolites of glycolysis, markedly decreased
triacylglyceride levels and decreased ATP levels.
Our plasma metabolomics analysis in eight patients with genetically proven ACO2 defi-
ciency identified significantly decreased TCA metabolites that are located downstream of the
metabolic block. We further found decreased glycolysis and fatty acid breakdown metabolites.
Generally these first studies in humans with ACO2 deficiency agree with the findings in the
Acon-knockdown flies. OXPHOS measurement in a fresh muscle biopsy of an affected patient
showed decreased respiratory chain enzyme activity indicating an impairment of oxidative
phosphorylation but was normal in two further patients (data not shown). Mitochondrial
respiratory chain dysfunction has been identified in a number of neurodegenerative disorders
[23–26] but so far there is no clear proof of consistent secondary mitochondrial dysfunction in
ACO2 deficiency.
In the following sections, we discuss individual metabolites of the presented metabolic pro-
file that result in the dysfunction of several metabolic energy pathways and provide more
insight into the broader metabolic effect of ACO2 deficiency.
TCA cycle metabolites and glutamate metabolism
We found significantly decreased cis-aconitate, isocitrate and α-ketoglutarate, metabolites that
are found downstream of the metabolic block, while other TCA intermediates including succi-
nate, malate and fumarate were not dramatically altered. These results indicate an impairment
of the citric acid cycle though some metabolites seem to be restored by anaplerotic reactions.
Alpha-ketoglutarate for example, serves as a major entry and exit point for carbon to and from
the Krebs cycle and is essential for the oxidation of fatty acids, amino acids, and glucose [27].
In the TCA cycle, AKG is produced by the oxidative decarboxylation of isocitrate catalyzed
by isocitrate dehydrogenase (IDH; S1 Fig). AKG can also be produced anaplerotically from
glutamate by oxidative deamination by glutamate dehydrogenase. Our finding of reduced
AKG in ACO2 deficient patients is intriguing as we observe slight elevation in plasma gluta-
mate levels. AKG levels are thus not restored by glutamate deamination. It moreover appears
that glutamate metabolism is secondarily affected although the mechanism is not yet clear. In
the adult-onset olivopontocerebellar neurodegeneration, decreased AKG levels combined with
increased glutamate levels have been associated with a partial deficiency of glutamate dehydro-
genase [28].
Neurotoxicity of ACO2 deficiency may be promoted by both increased glutamate and
reduced AKG levels. Glutamate-induced neurotoxicity is a well-established concept that may
contribute to brain damage and epileptic activity in ACO2 deficiency. Metabolomics data
showed elevated glutamate levels, although routine analysis of glutamate in serum was normal
in most of our patients. However, intracellular increase of glutamate may induce alterations of
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membrane potentials and ion channels. AKG can directly protect cellular macromolecules
against ROS damage during seizure [29]. Reduced AKG levels thus result in an impaired pro-
tection from oxidative stress.
Glycolysis metabolites
Mitochondrial aconitase catalyzes the stereospecific isomerization of citrate to isocitrate. Cit-
rate sits at the crossroad of glycolysis and fatty acid synthesis and as such acts a key regulator
of energy production. Citrate exerts a negative feedback on glycolysis through negative regula-
tion of phosphofructokinase 1 and 2 [30, 31]. Acon-knockdown flies showed significantly
decreased intermediate metabolites of glycolysis, namely glucose-1-phosphate, glucose-
6-phosphate, fructose-6-phosphate, glyceraldehyde-3-phosphate, 2-phosphoglycerate, 3-phos-
phoglycerate, phosphoenolpyruvate (PEP) and pyruvate [22]. In our patient cohort, we could
not identify elevated citrate levels, however, citrate may be quickly processed into other associ-
ated secondary pathways. We observed markedly decreased C6-sugar phosphates and phos-
phoenolpyruvate indicating impaired glycolysis.
Metabolites of fatty acid metabolism
Citrate also promotes fatty acid synthesis through allosteric activation of acetyl-CoA carboxyl-
ase [32, 33]. Acetyl-CoA carboxylase generates malonyl-CoA, an allosteric inhibitor of carni-
tine palmitoyltransferase-1 that controls the influx of long chain fatty acids into mitochondria
for β-oxidation [34, 35]. Consecutively, we observed significantly decreased α, β-hydroxybuty-
rate as an indicator of low fatty acid breakdown. This is consistent with Cheng et al., who
found markedly decreased triacylglyceride levels in the Acon-knock-down flies at day 3 after
birth, indicating an activation of fatty acid synthesis for alternative energy storage [22].
Mitochondrial oxidative phosphorylation
Decreased ACO2 activity results in slowed generation of NADH and FADH2 that are required
electron carriers for oxygen reduction in the electron transport chain (ETC) coupled with oxi-
dative phosphorylation. Limited electron transport through the ETC consequently decreases
ATP production [36] and leads to secondary mitochondrial respiratory chain dysfunction. In
the Acon-knockdown flies, ATP content was reduced indicating an impairment of down-
stream oxidative phosphorylation. One single patient (F4-P1) of our cohort had OXPHOS
measurement in a fresh muscle biopsy that showed reduced complex I/III enzyme activity,
while complex II and II/III showed a borderline enzyme activity (data not shown). Impairment
of oxidative phosphorylation leads to increased reactive oxygen species (ROS) that finally
result in cell death [37]. Mitochondrial aconitase (ACO2) contains an 4Fe-4S cluster that is
particularly sensitive to mitochondrial reactive oxygen species such as superoxide radical O2-
[37]. Oxidative inactivation of 4Fe-4S cluster results in loss of an non-ligated iron atom (i.e.
3Fe-4S) and consecutively in formation of H2O2 radicals and accumulation of Fe
2+ [37].
Neurotoxicity induced by mitochondrial oxidative stress has been demonstrated for several
neurodegenerative disorders. Furthermore, reduced aconitase activity has been found in Hun-
tington disease, progressive supranuclear palsy, Friedreich ataxia [23, 38, 39] and Alzheimer’s
disease [40].
Conclusion
Here we report for the first time a potentially diagnostic plasma metabolic profile for ACO2
deficiency. The profile includes several metabolites of the TCA cycle and associated metabolic
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pathways. The complex pathomechanisms of ACO2 deficiency are not yet completely eluci-
dated. However, investigations in the Acon-knockdown fly model and our own metabolomics
data indicate that this genetic defect affects three major energy pathways, namely oxidative
phosphorylation, glycolysis and fatty acid oxidation. Neurotoxicity may be caused by the accu-
mulation of glutamate, the formation of radical species and the lack of ATP. We suggest that
following complete validation of this metabolome profile, plasma be analyzed in patients who
present with a combination of hypotonia, intellectual disability, seizures, optic atrophy and
cerebellar atrophy on MR images. Herein we demonstrate that metabolome profiling is a pow-
erful tool to characterize disease mechanisms and pathogenicity of mutations.
Supporting information
S1 Fig. The core reactions of the citric acid cycle [1]. Aconitase (aconitate hydratase; EC 4.2.
1.3) catalyzes the stereospecific isomerization of citric acid to isocitric acid. The reaction inter-
mediate cis-aconitic acid is indicated in brackets.
(TIF)
S2 Fig. Mass spectral fragmentation pattern matching for isocitrate. Fragmentation pat-
terned for the isobaric reference materials (citric and isocitric acid) were compared to the
ACO2-deficient plasma MS/MS data.
(TIF)
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